Development of AI Tool for Precision Therapeutic & Prognosis on Early Dementia and Post-Stroke Rehabilitation

精准治疗AI工具开发

• 批准号: 10072268
• 金额: $ 89.59万
• 依托单位: BRAINBERRY LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072268
• 关键词: Development; AI; Tool; Precision; Therapeutic

The proposed COSMA neurofeedback system is a self-management solution but also a therapeutic system that provides a cognitive map response for each game played which includes (1) cognitive scores and (2) brain profile responses. The cognitive map produced will help the user, carer, and clinician to understand the patients' cognitive enhancement and the brain's current capacity to adapt and prevent the cognitive and psychological related issues as a secondary tool.This proposed technology is aimed at providing precision medicine for preventing dementia progression at early stages with a early diagnosis and a continuous monitoring measures that will provide quicker recovery and long-term support for dementia and post-stroke patients.The benefits of the technology are: (1) non-invasive; (2) improved mental ability for dementia/stroke patients; (3) can provide early/quick recovery treatment; (4) ensures patient's longer independence; (5) reduced reliance upon NHS and improves UK economy; and (6) will strengthen the UK as a leader in dementia and stroke research.

所提出的COSMA神经反馈系统是一种自我管理解决方案，也是一种治疗系统，它为每次玩游戏提供认知地图反应，其中包括(1)认知得分和(2)大脑特征反应。生成的认知地图将帮助使用者、护理人员和临床医生了解患者的认知增强以及大脑当前适应和预防认知和心理相关问题的能力，作为辅助工具。这项拟议的技术旨在提供精准医学，通过早期诊断和持续监测措施，在早期阶段预防痴呆症的进展，为痴呆症和中风后患者提供更快的恢复和长期支持。该技术的优点是：(1)非侵入性；(2)改善痴呆/脑卒中患者的心智能力；(3)能够提供早期/快速康复治疗；(4)保证患者更长的独立性；(5)减少对国民保健服务的依赖，改善英国经济；(6)将加强英国在痴呆症和中风研究方面的领导地位。